Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O94905
UPID:
ERLN2_HUMAN
Alternative names:
Endoplasmic reticulum lipid raft-associated protein 2; Stomatin-prohibitin-flotillin-HflC/K domain-containing protein 2
Alternative UPACC:
O94905; A0JLQ1; A8K5S9; B4DM38; D3DSW0; Q6NW21; Q86VS6; Q86W49
Background:
Erlin-2, also known as Endoplasmic reticulum lipid raft-associated protein 2, plays a crucial role in the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors and the regulation of cellular cholesterol homeostasis. It is a component of the ERLIN1/ERLIN2 complex, influencing the SREBP signaling pathway and potentially the ER retention of the SCAP-SREBF complex.
Therapeutic significance:
Erlin-2's involvement in Spastic paraplegia 18, a neurodegenerative disorder, underscores its therapeutic significance. Understanding the role of Erlin-2 could open doors to potential therapeutic strategies for treating this severe form of spastic paraplegia and related psychomotor retardation.